Edwards Lifesciences - EW Stock Forecast, Price & News

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EW shares.
View EW analyst ratings or view top-rated stocks.

20 analysts have issued 1-year target prices for Edwards Lifesciences' stock. Their EW share price forecasts range from $106.00 to $144.00. On average, they expect the company's share price to reach $125.10 in the next twelve months. This suggests a possible upside of 44.7% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $129.55 at the beginning of 2022. Since then, EW shares have decreased by 33.2% and is now trading at $86.48.
View the best growth stocks for 2022 here.

Edwards Lifesciences saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 6,540,000 shares, an increase of 77.7% from the August 31st total of 3,680,000 shares. Based on an average daily trading volume, of 2,570,000 shares, the short-interest ratio is presently 2.5 days. Currently, 1.1% of the company's shares are sold short.
View Edwards Lifesciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our EW earnings forecast.

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings results on Thursday, July, 28th. The medical research company reported $0.63 EPS for the quarter, meeting the consensus estimate of $0.63. The medical research company earned $1.37 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a trailing twelve-month return on equity of 24.77%. The company's revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.64 EPS.
Read the conference call transcript.

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $2.50-$2.50 for the period, compared to the consensus estimate of $2.56. The company issued revenue guidance of $5.35 billion-$5.55 billion, compared to the consensus revenue estimate of $5.71 billion.

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Beese Fulmer Investment Management Inc. (0.02%), Bath Savings Trust Co (0.02%), Abner Herrman & Brock LLC (0.01%), First Hawaiian Bank (0.00%), Csenge Advisory Group (0.00%) and Capital Investment Advisors LLC (0.00%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EW stock can currently be purchased for approximately $86.48.

Edwards Lifesciences (NYSE:EW) has a market capitalization of $53.61 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.31 on an earnings per share basis.

The company employs 15,700 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.